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A bioequivalence of two brands of 10% enrofloxacin was tested in broiler 
chickens using a parallel design at 20 mg/kg bodyweight orally. Blood was 
sampled before and after drug administration for 24 hours. Plasma enrofloxacin 
concentrations were analyzed using microbiological assay. Peak plasma 
concentrations (Cmax), 1.00 ± 0.05 and 0.91 ± 0.02 μg/ml were obtained in 
chickens given Reference and Test brands respectively at 1.00±0.01 and 2.00 ± 
0.17 hours respectively. Areas under plasma concentration-time curve (AUC0-
24) were 3.79 ± 0.07 and 4.90 ± 0.01 μg/ml for Reference and Test brands 
respectively. Ratios of Cmax, and AUC0-24(T/R) were 0.91 and 1.29 respectively. 




are therefore bioequivalent and interchangeable. 
 
 




Enrofloxacin is a third generation, 
synthetic and broad spectrum 
bactericidal Fluoroquinolone 
exclusively used in veterinary 
medicine (Sheer, 1990; Vancutsem et 
al., 1990). It has an excellent 
antibacterial activity against most 
pathogenic bacterial organisms that are 
resistant to other antibacterial agents 
(Bauditz, 1987; Elmas et al., 2000). 
Pharmacokinetic studies have indicated 
that enrofloxacin is rapidly absorbed 
and well distributed throughout the 
body following oral and intramuscular 
administrations in animals (Soliman, 
2000; Randall et al., 2006). This 
supports its frequency of use in 
treating avian invasive infectious 
diseases like fowl typhoid, 
colibacillosis, pasteurollosis and 
mycoplasmosis. Most brands of 
enrofloxacin have been demonstrated 
not to be bioequivalent with the 
innovator formulation in animal 
studies conducted outside Nigeria on 
the formulations available in such 
places (Sumano et al., 2001a; Sumano 
et al., 2006).   
There are arrays of multisource brands 
of enrofloxacin in the market. Most of 
these brands do not give the desired 
therapeutic outcome when compared 
with the pioneer product (baytril
®
) 




which is not available currently in the 
Nigerian market. The significance of 
enrofloxacin in veterinary medicine 
and lack of documented blood-level 
bioequivalence evaluation of the 
abundant imported brands in Nigeria 
has informed this study. 
 
MATERIALS AND METHOD 
Study Products  
Kenflox
®
 (10% enrofloxacin) from 
Holland (Batch No. 0811703, Exp. 03-
2011) was used as test brand while 
conflox-vet
®
 (10% enrofloxacin) from 
India (Batch No. 70002, Exp. 06-2012) 
was used as the reference brand due to 
its widespread availability and 
effectiveness. Pure enrofloxacin (≥ 
98%) from Sigma- Aldriech, USA was 
used as a standard. 
 
Experimental Subjects 
Twenty four broiler chickens, 8 weeks 
old, weighing 2.5 – 3.0 kg body 
weights (b.w) were used. Fifty day-old 
broiler chicks were commercially 
sourced and managed under deep litter 
system. They were vaccinated against 
most common infectious poultry 
diseases. The feed was formulated 
without inclusion of drugs. At 5 weeks 
old, the apparently healthy chickens 
(24 chickens) were separated and 
allowed to acclimatize in the 
experimental environment for three 
weeks during which no drug, except 




A randomized, single oral dose and 
parallel method was employed. The 
animals were assigned to two groups, 
A-reference and B-test (n = 12). Feeds 
and water were withdrawn 8 and 2-
hours respectively before drug 
administration. This was to reduce 
absorption variability due to drug-feed 
interaction and over dilution of the 
drug respectively (Randandt et al., 
1992). Animals in each group were 
weighed individually and their dosages 
calculated based on weights (20 mg/kg 




animals in group B were given the test 
brand (kenflox
®
). The drugs were 
given per os using an improvised oral 
canula attached to a 5 ml syringe. The 
animals were monitored and those that 
regurgitated were excluded from the 
experiment. Thereafter, feeds and 
water were re-introduced 2 hours post 
drug administration. 
 
Sampling and Processing 
Blood samples were obtained by 
venipuncture through the left or right 
brachial veins into EDTA tubes at 
times 0 (pre treatment), 0.25, 0.5, 1, 2, 
3, 4, 6, 8, 10, 12, and 24 hours (post 
treatment). It was ensured that the 
differences between the targeted and 
the actual sampling times were not 
more than 2 minutes. The samples 
were centrifuged at 3000 rpm for 10 
minutes at 37
°
C and the supernatant 
(plasma) collected into plastic micro-
tubes. These were stored at - 4
°
C and 
analyzed 24 hours following sampling. 
 
Plasma Analysis of Enrofloxacin 
A quantitative-qualitative agar 
diffusion microbiological assay using 
blank disks (7 mm) was employed 
(Kwasi et al., 1999; Ehab et al., 2008; 
Andres et al., 2009). This assay is 
based on the concentration–dependent 
variation of the inhibitory effect of 
antibiotics on a test bacterium, 
producing a concentration-response 
(zone of inhibition) linear relationship. 
The test organism used was 
Escherichia coli, NCTC10418 on 
nutrient agar medium ((Bryant, 1981; 
Dowling et al., 1995). 
Briefly described, the blank disks were 
adequately saturated with 
enrofloxacin-spiked blank and treated 
plasma samples separately. The 




impregnated disks were then carefully 
and firmly placed onto the surface of 
the E.coli-seeded nutrient media Petri 
dishes (n = 3). This was allowed to 
stand for 5 minutes to allow for 
diffusion, after which they were 
incubated at 37
°
C overnight in an 
aerobic condition. Thereafter, the 
diameters of inhibition zones were 
measured with the aid of a transparent 
rule to the nearest millimeter. Each 
sample was replicated thrice and 
analyzed similarly.  
A seven-point standard curve was 
constructed by spiking blank chicken 
plasma with concentrations of 
analytical enrofloxacin ranging from 
0.02 to 5.00 μg/ml. The plot of 
enrofloxacin plasma concentrations 
versus diameters of inhibition zone 
was linear with a correlation 
coefficient of 0.89. Plasma 
concentrations of enrofloxacin were 
determined by comparing the zone of 
inhibition diameters with the standard 
curve. The absence of interfering 
endogenous compounds was 
demonstrated in antibacterial-free 
plasma obtained at time 0 
(pretreatment) which showed no 
visible zone of inhibition around the 
impregnated disks. The limit of 
quantification (LOQ) defined visually 
as the smallest amount of drug that still 
produced a clearly distinguishable 
inhibition zone around the edges of 
enrofloxacin-saturated disks on 
nutrient agar media was 0.02 μg/ml 




Pharmacokinetics and Statistical 
Analyses 
Plasma concentrations of enrofloxacin 
versus time data obtained during the 
study were utilized for calculating 
various pharmacokinetic variables 
using a non-compartmental analysis. 
The peak concentrations, Cmax and 
time to peak, Tmax were obtained from 
the plasma concentration-time data 
directly. The areas under the plasma 
concentration of enrofloxacin time 
curves from time 0 to the last sample 
collected (AUC0-24) were calculated 
using linear trapezoidal method 
(Baggot, 2001). While AUC0-∞ was 
derived from AUC0-24 + AUC24-∞, 
where AUC24-∞ = C24/ß. For 
bioequivalence evaluation, the ratios of 
Cmax (T/R), AUC0-24 (T/R) and AUC0-∞ 
(T/R) were calculated. Values within 
the bioequivalence acceptable range at 
90% confidence interval, 0.80 – 1.25 
were considered for accepting the null 
hypothesis of bioequivalence between 
the reference and the test brands 
((EMEA, 2006). 
 
Statistical analysis on the plasma 
concentration-time and 
pharmacokinetic profiles were carried 
out with two-way analysis of variance 
(ANOVA). Significant difference at p 
< 0.05 was determined using Dunett 
test. All data were reported as mean ± 
SEM.       
 
RESULTS 
The composite data and curves depicting 
the mean plasma concentrations (mean ± 
SEM) of enrofloxacin versus time 





 brand at the dose level 
of 20 mg/kg  b.w to broiler chickens are 
presented in Table I and Figure 1 
respectively. 
 
The mean plasma concentrations-time 
profiles for the two pharmaceutical 
formulations were dissimilar throughout 
the time of sampling. But the mean 
plasma concentrations of enrofloxacin in 
all the groups were never below the 
reported minimum inhibition 
concentration (0.008 – 0.06 μg/ml) for 
the common pathogenic bacterial 
organisms of avian species (Sanjib et al., 
2005). The mean maximum plasma 
concentration of enrofloxacin, Cmax in 
animals given the conflox-vet
®
 and 






 formulations were 1.00 ± 0.05 
and 0.91 ± 0.02 μg/ml respectively. 
While the time to attain these peak 
concentrations (Tmax) were 1 and 2 hours 
respectively. 
 
Based on the number of linear decay 
components in the mean plasma 
concentration of the drug versus time 
data plotted on a semi-logarithmic scale 
over 24 hour period for the two brands, a 
two compartment open-model was 
selected to describe the plasma 
disposition kinetics of enrofloxacin in 
broiler chickens. The general bi-
exponential equation fitted to the mean 
plasma concentration versus time data 





, where A and B represent 
intercepts on the y-axis; C(t) is the mean 
plasma concentration at time t; -kα  is 
the estimated first-order rate constant of 
absorption, -k ß is the estimated first-
order rate constant of elimination of the 
drug. 
 
The statistical analysis of the 
pharmacokinetic variables that describes 
the rate (Cmax) and extent of absorption 
(AUC) of enrofloxacin are presented in 
Table II. While the data depicting the 
bioequivalence point estimates and the 
acceptable range at 90% confidence 
interval is presented in Table III. The 
calculated value for Cmax (T/R), AUC0-24 
(T/R) and AUCo-∞ (T/R) were 0.91, 
1.29 and 1.29 respectively.  
All the experimental animals remained 
healthy during and after the study. 
 
DISCUSSION 
The effectiveness of a drug is partly 
dependent on its formulation, route of    
administration and metabolic pattern 
(Alvinerie et al., 1999). These factors 
determine the plasma concentration-time 
profile of the drug. Following 
administration of a single oral dose (20 
mg/kg b.w) of 10% enrofloxacin 
formulations to healthy broiler chickens, 
therapeutic concentration were achieved 
15 minutes post administration in all the 
animals. The concentration was detected 
up to 10 and 12 hours in the plasma of 





 brands respectively. Although 
there was a significant difference (p < 
0.05) in mean plasma concentrations of 
enrofloxacin between the two groups, the 
plasma concentrations at all time points 
in both groups were 10 fold higher than 
the minimum inhibition concentration, 
MIC90 reported for enrofloxacin in 
chickens against most pathogenic 
bacterial organisms in avian species 
(Sanjib et al., 2005). 
This suggests that the two brands when 
given at this dose will be clinically 
effective and there will be reduced 
chances of the emergence of resistant 
bacterial strains (Drusano, 1993; Baggot, 
2001). Differences in the formulation of 
the drugs could be responsible for the 
significant difference in the mean plasma 
concentrations of enrofloxacin between 
the two brands.   




Table I. Mean plasma concentrations of enrofloxacin (µg/ml) in broiler chickens 
following  oral administration of conflox-vet
®
 (reference) and kenflox
®
 (test) 
formulations at a dose level of 20 mg/kg b.w Values are mean ± SEM (n = 12) 
 
Time  post  
Administration (hour) 











0.25 0.38 ± 0.018 0.13 ± 0.023 65.79 
0.50 0.77 ± 0.035 0.61 ± 0.035 20.78 
 1.00 1.00 ± 0.055 0.83 ± 0.038 17.00 
2.00 0.86 ± 0.030 0.91 ± 0.024* 5.00 
3.00 0.65 ± 0.020 0.84 ± 0.035 29.23 
4.00 0.42 ± 0.027 0.54 ± 0.035* 12.00 
6.00 0.19 ± 0.036 0.24 ± 0.038 26.32 
8.00 0.12 ± 0.025 0.17 ± 0.025 41.67 
10.00 0.09 ± 0.000 0.14 ± 0.018 55.56 
12.00 ND 0.11 ± 0.000 NA 
24.00 ND ND NA 
NB:  Values are mean ± SEM (n = 12); *The mean difference is significant at the p < 
0.05 level from those of reference drug; Not detected (ND) and not applicable 
(NA) 
 
Table II. Mean pivotal pharmacokinetic parameters of bioequivalence testing for two 
oral formulations of 10% enrofloxacin 









Cmax (µg/ml) 1.00 ± 0.055 0.91 ± 0.024 
AUC0-24(µg.h/ml) 3.79 ± 0.072 4.90 ± 0.007* 
AUC0-∞(µg.h/ml) 4.35 ± 0.072 5.59 ± 0.007* 
NB: Values are mean ± SEM (n=12). *The mean difference is significant at the p < 0.05 
level from those of the reference drug 
 
Table III. Bioequivalence ratio of test and reference brands of 10% enrofloxacin oral 
formulations 
 Cmax (µg/ml) AUC0-24(μg.h/ml) AUC0-∞(μg.h/ml) 
Reference(conflux-vet
®
) 1.00 ± 0.06 3.79 ± 0.07 4.35 ± 0.07 
Test (kenflox
®
) 0.91 ± 0.02 4.90 ± 0.07 5.59 ± 0.07 
Point estimate 0.91 1.29 1.29 
Acceptable range 0.80 – 1.25 0.80 – 1.25 0.80 – 1.25 












































     




















Figure 1. Plasma concentration-time 
profile curves of enrofloxacin after oral 
administration of reference (conflox-
vet
®
) and test (kenflox
®
) brands in 











 described the plasma 
disposition kinetics of enrofloxacin in all 
the experimental subjects used. This 
implies that the pharmacokinetic of 
enrofloxacin following a single oral 
administration to broiler chicken at the 
dose level of 20 mg/kg b.w can be 
described by a two compartmental open-
model. This is in agreement with the 
previous studies in birds, chickens, 
rabbits, dogs and ruminants (Broome et 
al., 1991; Flammer et al., 1991; Walker 
et al., 1992; Anadon et al., 1995; Kwasi 
et al., 1999; Elmas et al., 2004). 
 
Although there was no significant 
difference (p >0.05) between the two 
groups, the mean plasma concentrations 
(Cmax) of enrofloxacin in the animals 
given Conflox-Vet
®
 formulation (1.00 ± 
0.004 µg/ml) was higher than those 
administered Kenflox
®
 (0.91 ± 0.024 
μg/ml). These values are considerably 
lower than those reported earlier in 
broiler chickens at a dose level of 10 
mg/kg (Anadon et al., 1995; DaSilva et 
al., 2006; Posyniak et al., 2007). But the 
mean Cmax in the present study is similar 
to those earlier reported in chickens 
(0.99 ± 0.08 μg/mg) (Kwasi et al., 1999). 
The time taken to attain the peak plasma 
concentration, Tmax of enrofloxacin was 
shorter in chickens administered 
conflox-vet
®
 (1 hour) than the group 
given kenflox
®
 brand (2 hours).  
 
The area under the drug concentration-
time curve (AUC) is a useful index for 
biological availability of the active 
moiety of a drug formulation (extent of 
absorption). In the present study, the 
mean AUC`0-24 and AUC0-∞ values for 
the two brands were significantly 
different (p < 0.05). The mean value 
observed in animals given kenflox
® 
formulation (4.90 ± 0.01 µg.h/ml) is 
higher than that obtained in the group 
administered brand conflox-vet
®
 (3.79 ± 
0.07 µg.h/ml). This is likely due to 
differences in formulations. The mean 
values of AUC0-24 obtained in this study 
are both higher and lower than or similar 
to values obtained earlier in broiler 
chickens (Knoll et al., 1999; Haritova et 
al., 2004; DaSilva et al., 2006). The 
differences are likely due to variations in 
the formulations used, dosages and 
routes of administrations. The mean 
values of AUC0-24, and AUC0-∞ for the 
two brands used in this study were 
significantly different (p < 0.05), 
suggesting that enrofloxacin plasma 
concentration-time profile produced by 
the two brands are not the same. This 
could explain the significant difference 




in the mean plasma concentration-time 
profile observed between the two groups. 
 
Bioequivalence refers to a comparison 
between generic formulations of a drug, 
or a product in which a change has been 
made in one or more of the ingredients 
or in the manufacturing process, and a 
reference dosage form of the same drug 
(Alvinerie et al., 1999). This study 
shows that the bioequivalence ratio for 
mean AUC0-24, AUC0-∞ and Cmax (T/R) 
of kenflox
®
 versus the reference products 
were 1.29, 1.29 and 0.91 respectively. 
These values were within the 
recommended range at the level of 90% 
confidence interval, 0.80 – 1.25
 
(Walker 
et al., 1992). The two brands of 10% 
enrofloxacin oral tested in this 
experiment could therefore be 
considered bioequivalent. 
CONCLUSION 
Since AUC reflects the access of 
enrofloxacin to the blood circulation 
(bioavailability), all the formulations 
seemed to be well absorbed after oral 
administration. The dosage regimen used 
in this study is sufficient to maintain an 
effective therapeutic plasma 
concentration of enrofloxacin when any 
of the two brands studied is used in 
broiler chickens. But the test 
formulation, kenflox
®
 is superior in 
terms of maintaining therapeutic 
concentration over a long time. Since 
bactericidal activity of Fluoroquinolones 
is concentration-dependent but not time 
dependent, the in vivo performance of 
these brands is anticipated to be 
equivalent (Craig, 1993; Baggot, 2001). 
The test formulation, kenflox
®
 by 
KEPRO BV, Holland is therefore 
bioequivalent to our reference product, 
conflox
®
-vet by Concept 
pharmaceuticals, India. The two brands 
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